Role of Nebulized Amphotericin B in the Treatment of Hemoptysis

more than five decades of clinical use, has long been employed in the management of invasive fungal infections.6 Nebulized amphotericin B has recently gained attention as a promising adjunctive local therapy for the control of hemoptysis in pulmonary fungal diseases.7 Previous studies have explored the role of nebulized amphotericin B, either alone or in comparison with systemic antifungal therapy, across various fungal lung infections. MethodsA prospective observational study was conducted at our tertiary care center.Clinical records of patients presenting with hemoptysis secondary to suspected or confirmed pulmonary fungal infections were included in the study.Data collected included demographic details, age, smoking status, prior history of pulmonary tuberculosis or antitubercular treatment (ATT), coagulation profile [international normalized ratio (INR)], radiological findings suggestive of fungal infection (aspergilloma, mycetoma, or invasive pulmonary aspergillosis), and concurrent antifungal or hemostatic therapy.Nebulization of amphotericin B deoxycholate was administered to patients every 12 hours for 7 days.Injection amphotericin B deoxycholate was reconstituted (50 mg) using 20 mL of normal AiMTo evaluate the role of nebulized amphotericin B on the severity and frequency of hemoptysis in patients with respiratory fungal infections.